Cara Therapeutics, Inc. (NASDAQ:CARA) Receives $83.52 Average Target Price from Analysts

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have been given a consensus recommendation of “Hold” by the five brokerages that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $83.52.

Separately, StockNews.com initiated coverage on Cara Therapeutics in a research note on Thursday. They issued a “sell” rating on the stock.

Cara Therapeutics Price Performance

Cara Therapeutics has a 1 year low of $8.13 and a 1 year high of $31.32. The firm has a market capitalization of $24.33 million, a P/E ratio of -0.25 and a beta of 0.41. The firm’s 50-day simple moving average is $15.19 and its two-hundred day simple moving average is $13.17.

Institutional Trading of Cara Therapeutics

Several institutional investors have recently bought and sold shares of CARA. Curi RMB Capital LLC purchased a new position in shares of Cara Therapeutics during the 4th quarter valued at approximately $277,000. Shay Capital LLC purchased a new position in Cara Therapeutics during the fourth quarter valued at $524,000. Finally, Rockefeller Capital Management L.P. acquired a new stake in shares of Cara Therapeutics in the fourth quarter valued at about $953,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.